It was US investors that largely bankrolled the biotech industry over the past 25 years. Is all that about to change? Michael Fitzgerald investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fitzgerald, M. Where the money is. Nat Biotechnol 24, 240–242 (2006). https://doi.org/10.1038/nbt0306-240
Issue Date:
DOI: https://doi.org/10.1038/nbt0306-240
This article is cited by
-
Public biotechnology 2005—the numbers
Nature Biotechnology (2006)